New combo therapy shows promise for Hard-to-Treat vulvar cancer
NCT ID NCT04430699
First seen Apr 07, 2026 · Last updated May 16, 2026 · Updated 5 times
Summary
This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (cisplatin) and radiation can shrink or control advanced vulvar cancer that cannot be removed by surgery. About 24 participants will receive this combination therapy. The goal is to see if more tumors respond compared to standard treatments alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VULVAR CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.